20-F: CASI Pharmaceuticals Divests China Operations, Focuses on CID-103

CASI Pharmaceuticals announced a strategic shift, divesting its China-based subsidiaries and pipeline assets to focus on the global development of its CID-103 drug candidate.

Summary

• CASI Pharmaceuticals has entered into a definitive agreement to sell its two wholly-owned subsidiaries in China and transfer certain regional rights to pipeline products BI-1206, CID-103 (in Asia excluding Japan), and Thiotepa to an entity wholly-owned by its Chairman and then CEO.
• This transaction marks a fundamental shift in the company's corporate structure and strategic focus, repositioning it as a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases.
• The company will concentrate its resources on the accelerated global development of CID-103, for which it retains rights in Japan and all non-Asian regions.
• CASI Pharmaceuticals also reported recurring operating losses, raising substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $748.1 million as of December 31, 2025.
• The company's ordinary shares were delisted from Nasdaq on February 26, 2026, and began trading on the OTCQB market under the ticker CASIF on April 14, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant operating losses, a going concern warning, delisting from Nasdaq, and ongoing legal disputes, despite the strategic focus on CID-103.

Positives

• Strategic pivot to focus on the development of CID-103, an anti-CD38 monoclonal antibody, for organ transplant rejection and autoimmune diseases.
• Retains rights to CID-103 in Japan and non-Asian regions for accelerated global development.
• Divestiture of China-based operations simplifies corporate structure and allows for resource concentration.
• Entered into a binding term sheet to resolve a dispute with Acrotech regarding the EVOMELA license agreement in April 2026.
• Received NMPA approval for thiotepa in February 2026, with plans for commercialization in China.

Negatives

• Recurring operating losses raise substantial doubt about the company's ability to continue as a going concern.
• Accumulated deficit of $748.1 million as of December 31, 2025.
• Net current liabilities of $36.2 million as of December 31, 2025.
• Net cash used in operating activities was $20.8 million for the year ended December 31, 2025.
• FOLOTYN's Import Drug Registration License expired as of August 25, 2025, leading to cessation of sales in China.
• EVOMELA faces intensified competition from domestically produced generic melphalan products in China.
• Ordinary shares delisted from Nasdaq on February 26, 2026, and began trading on OTCQB market.
• The company is involved in arbitration proceedings against Juventas concerning CNCT19 agreements, with a final award expected by June 30, 2026.
• The company's ownership in CASI China and CASI Wuxi has been frozen due to the ongoing arbitration with Juventas, hindering the spin-off transaction.

Risks

• Uncertainty regarding the completion of the divestiture of China-based operations due to judicial freeze on Target Equity Interests.
• Potential for future share issuances to cause substantial dilution to existing shareholders.
• Difficulty in executing the business strategy on a global basis.
• Inability to enter into strategic partnerships for development, commercialization, manufacturing, and distribution of product candidates.
• Legal or regulatory developments in China that could adversely affect operations.
• Lack of experience in manufacturing products and uncertainty about resources and capabilities for clinical or commercial scale manufacturing.
• Inability to predict when or if product candidates will be approved for marketing by regulatory authorities.
• Need for additional capital and uncertainty of securing additional funding on favorable terms.
• Risks associated with product candidates and other early-stage products under development.
• Uncertainty related to the ongoing arbitration proceedings between the company and Juventas regarding CNCT19 license agreements.
• Potential for the company's largest shareholder and Chairman to have interests that differ from other shareholders.
• Risks related to the success of a new manufacturing facility by CASI Wuxi.
• Risks related to the inclusion status of drug products in the National Reimbursement Drug List.
• Risks related to the resolution of the clinical hold placed by the FDA on CID-103 IND application.
• Disagreement with Acrotech regarding the termination of agreements for EVOMELA.

Future Outlook

The company is focused on the accelerated global development of CID-103 for organ transplant rejection and autoimmune diseases. The company expects to require additional liquidity to continue operations over the next 12 months and is exploring various financing options. The company's strategy will shift to generic melphalan products in the future.

Management Comments

• The Company believes this initiative aligns with its strategic pivot toward developing CID-103 for the treatment of organ transplant rejection and autoimmune diseases.
• The Company expects to retain the rights related to CID-103 (in Japan and non-Asian regions), EVOMELA, FOLOTYN, CNCT19 and CB-5339, and remain firmly committed to progressing CID-103 at an accelerated pace.

Industry Context

StockSavvy.ai notes that CASI Pharmaceuticals' strategic pivot away from its China-based operations and focus on CID-103 aligns with a trend of biopharmaceutical companies streamlining their portfolios to concentrate on promising drug candidates with global development potential. The delisting from Nasdaq and move to OTCQB highlights the significant financial and operational challenges faced by companies with recurring losses and the need for substantial capital to advance clinical-stage assets.

Comparison to Industry Standards

• The company's net loss of $48.1 million for the year ended December 31, 2025, and accumulated deficit of $748.1 million, are significant relative to its current revenue streams, indicating a high burn rate typical of early-stage biopharmaceutical companies, but also raising concerns about long-term viability without substantial funding.
• The company's reliance on third-party distributors for EVOMELA and FOLOTYN, and the potential for supply chain disruptions or distributor issues, is a common challenge in the pharmaceutical industry, particularly for companies with limited market penetration.
• The company's R&D expenses of $6.3 million in 2025, while reduced from prior years, are still substantial and reflect the high cost of drug development, a critical factor for success in the biopharmaceutical sector.

Legal Proceedings

• CASI is involved in arbitration proceedings against Juventas concerning the CNCT19 Agreements, with a final award expected by June 30, 2026.
• A dispute with Acrotech concerning the EVOMELA License Agreement was resolved through an amicable settlement and binding term sheet in April 2026.

Related Party Transactions

• The company entered into a convertible note purchase agreement with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He, for US$20 million.
• Huiying Memorial Foundation, associated with Dr. He, purchased 230,000 ordinary shares from the ATM offering.
• Panacea Venture Healthcare Fund II, L.P., associated with director James Huang, purchased 1,500,000 ordinary shares from the ATM offering.
• The company entered into an equity and assets transfer agreement with Kaixin Pharmaceuticals Inc., an entity wholly-owned by Dr. Wei-Wu He, to sell its China-based subsidiaries and certain pipeline assets.
• The company entered into an Equity Transfer Agreement with PAT and Wuxi Zhihe Daukang Phase II Venture Capital Partnership, of which Dr. Wei-Wu He is a general partner, to acquire equity interest in PAT.
• The company entered into a service agreement with Human Longevity Inc. (HLI), where Dr. Wei-Wu He is the Executive Chairman, for office facilities.

Stakeholder Impact

• Shareholders may experience dilution due to potential future share issuances.
• The delisting from Nasdaq and trading on OTCQB may impact liquidity and investor confidence.
• The ongoing legal proceedings with Juventas could adversely impact the commercialization of CNCT19 and the company's results of operations and financial condition.
• The company's ability to continue as a going concern raises concerns for investors, suppliers, and employees.

Next Steps

• Continue global development of CID-103.
• Manage other retained assets, including EVOMELA, FOLOTYN, CNCT19, and CB-5339.
• Negotiate a longer-form settlement agreement with Acrotech.
• Monitor relevant developments and take commercially reasonable measures with respect to the commercialization plan of FOLOTYN in China.
• Continue negotiations with the local Wuxi government on the further treatment of the land development grant.
• Explore opportunities for further equity financing.

Key Dates

Recommendation

While the strategic focus on CID-103 presents a potential long-term upside, the company's current financial instability, recurring losses, delisting from Nasdaq, and ongoing legal disputes create significant near-term risks. A 'hold' recommendation reflects a cautious approach, awaiting further clarity on financing, clinical development progress, and resolution of legal matters before considering a more definitive investment stance.

Keywords

CASI Pharmaceuticals, SEC Filing, Form 20-F, CID-103, Biopharmaceutical, China Operations Divestiture, Corporate Restructuring, Clinical Stage, Organ Transplant Rejection, Autoimmune Diseases, Nasdaq Delisting, OTCQB